Watch More Highlights

Lindsey M. Lyle, MS, PA-C, of the University of Colorado Anschutz Medical Campus, discusses phase III data from the PRINCE study, which showed that patients with paroxysmal nocturnal hemoglobinuria who were naive to complement-inhibitor treatment demonstrated meaningful hematologic and clinical improvements following 26 weeks of treatment with the monoclonal antibody pegcetacoplan (Abstract 606).

Copyright © 2010-2021 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.